首页 | 本学科首页   官方微博 | 高级检索  
检索        

糖肾平胶囊对糖尿病肾病大鼠肾脏保护作用及其对肾组织单核细胞趋化因子-1蛋白及mRNA表达的影响
引用本文:赵宗江,豆小妮,张新雪,杨美娟.糖肾平胶囊对糖尿病肾病大鼠肾脏保护作用及其对肾组织单核细胞趋化因子-1蛋白及mRNA表达的影响[J].中国实验方剂学杂志,2009,15(1):32-36.
作者姓名:赵宗江  豆小妮  张新雪  杨美娟
作者单位:北京中医药大学,北京,100029
基金项目:教育部长江学者和创新团队发展计划,国家自然科学基金重点项目,高等学校学科创新引智计划,北京市中医管理局资助项目 
摘    要:目的:探讨糖肾平胶囊对糖尿病肾病大鼠肾脏保护作用及其对肾组织单核细胞趋化因子(MCP-1)蛋白及mRNA表达的影响。方法:雄性SD大鼠,50只,按体重均匀分出正常组10只,其余40只,腹腔注射链脲佐菌素造模。将造模成功的大鼠按血糖水平分为模型组、厄贝沙坦组、糖肾平胶囊组,用药12周。每周称量体重;4,8,12周后分笼收集24 h尿液检测24 h尿蛋白定量,处死大鼠行血液生化指标BUN、Scr、TG检测,肾组织行HE、Mallory染色,观察病理形态学改变,采用免疫组化、原位杂交分析肾组织MCP-1蛋白及mRNA的表达。结果:模型组大鼠摄食减少、精神不振、活动迟缓、尿量减少、体重减轻以及肾组织病理改变,而厄贝沙坦组和糖肾平胶囊组均有不同程度的改善,且糖肾平胶囊组优于厄贝沙坦组;正常组肾小管上皮细胞、肾间质细胞胞浆有少量MCP-1蛋白及mRNA表达;模型组则呈强阳性表达。糖肾平胶囊组MCP-1蛋白及mRNA的表达较模型组明显减少(P<0.05)。结论:糖肾平胶囊可能通过对肾组织MCP-1蛋白及mRNA表达下调而发挥治疗和预防糖尿病肾病的作用。

关 键 词:糖肾平胶囊  糖尿病肾病  链脲佐菌素  单核细胞趋化因子-1
收稿时间:2008/1/29 0:00:00

Effects of Tangshenping Capsule on the Renal Protection and Expressions of MCP-1 and mRNA in Streptozotocin-induced Diabetic Nephropathy Rats
ZHAO Zong-jiang,DOU Xiao-ni,ZHANG Xin-xue,YANG Mei-juan.Effects of Tangshenping Capsule on the Renal Protection and Expressions of MCP-1 and mRNA in Streptozotocin-induced Diabetic Nephropathy Rats[J].China Journal of Experimental Traditional Medical Formulae,2009,15(1):32-36.
Authors:ZHAO Zong-jiang  DOU Xiao-ni  ZHANG Xin-xue  YANG Mei-juan
Institution:Beijing University of Traditional Chinese Medicine,Beijing 100029,China
Abstract:Objective:To observe the effects of Tangshenping Capsule on the expressions of MCP-1 and mRNA in streptozotocin induced diabetic nephropathy rats.Methods: 50 SD rats were randomly divided into normal control group(n=10),model group(n=40).Then the saccessfully modeled rats were re-divided into model group,irbesartan group and Tangshenping Capsule group.After administration of 12 weeks,the rats were sacrificed,Pathological changes in renal tissue were observed by HE and Mallory Staining.Using immunohistochemistry and hybridization analysis,renal tissue MCP-1 protein and mRNA expression were determined.Results: The model group showed reduction in appetite,activities,urine volume,body weight and pathological damages in kidney.Irbesartan and Tangshenping Capsule improved the above mentioned changes.Tangshenping Capsule group was superior to irbesartan group.There are some differences;in normal group and the treatment group renal tubular epithelial cells and interstitial cells showed mild MCP-1 and mRNA expression,in the model group there was a strong expression.Tangshenping Capsule significantly reduced the MCP-1 and mRNA expression(P<0.05).Conclusion: Tangshenping Capsule plays a role in treatment and prevention of DN via regulating MCP-1 and mRNA balance.
Keywords:Tangshenping Capsule  diabetic nephropathy  streptozotocin  MCP-1
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号